Mdm-2: 'Big Brother' of p53

Journal of Cellular Biochemistry

Volumn 64, Issue 3, 1997, Pages 343-352

  Momand, Jamil ^a   Zambetti, Gerard P ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

CARCINOGENESIS; CELL CYCLE; GROWTH REGULATION; MUTATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTO ONCOGENE; REVIEW; STRUCTURE ANALYSIS; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; ANIMALS; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; DNA REPAIR; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HOMEOSTASIS; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2;

RAPHIA FRATER;

EID: 0031038269     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(19970301)64:3<343::AID-JCB1>3.0.CO;2-V     Document Type: Review

References (98)

1. Adesina A, Nalbantoglu J, Cavenee W (1994): p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 54:5649-5651.
2. Barak Y, Oren M (1992): Enhanced binding of a 95 kDa protein in cells undergoing p53-mediated growth arrest. EMBO J 11:2115-2121.
3. Barak Y, Juven T, Haffner R, Oren M (1993): mdm2 expression is induced by wild type p53 activity. EMBO J 12:461-468.
4. Berberich S, Cole M (1994): The mdm-2 oncogene is translocated and overexpressed in a murine plasmacytoma cell line expressing wild-type p53. Oncogene 9:1469-1472.
5. Beroud C, Verdier F, Soussi T (1996): p53 gene mutation: Software and database. Nucleic Acids Res 24:147-150.
6. Boddy M, Freemont P, Borden K (1994): The p53-associated protein MDM-2 contains a newly characterized zinc-binding domain called the RING finger. TIBS 19:198-199.
7. Bueso-Ramos C, Yang Y, deLeon E, McCown P, Stass S, Albitar M (1993): The human MDM-2 oncogene is overexpressed in leukemias. Blood 82:2617-2623.
8. Cahilly-Snyder L, Yang-Feng T, Francke U, George D (1987): Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell Mol Genet 13:235-244.
9. Chen J, Marechal V, Levine A (1993): Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13:4107-4114.
10. Chen J, Wu X, Lin J, Levine A (1996): Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16:2445-2452.
11. Clarke A, Purdie C, Harrison D, Morris R, Bird C, Hooper M, Wyllie A (1993): Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852.
12. Cordon-Cardo C, Latres E, Drobnjak M, Oliva M, Pollack D, Woodruff J, Marechal V, Chen J, Brennan M, Levine A (1994): Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794-799.
13. Corvi R, Savelyeva L, Breit S, Wenzel A, Handgretinger R, Barak J, Oren M, Amler L, Schwab M (1995): Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 10:1081-1086.
14. Donehower L, Harvey M, Slagle B, McArthur M, Montgomery C, Butel J, Bradley A (1992): Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215-221.
15. Dubs-Poterszman M, Tocque B, Wasylyk B (1995): MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene 11:2445-2449.
16. El-Deiry W, Tokino T, Velculescu V, Levy D, Parsons R, Trent J, Lin D, Mercer W, Kinzler W, Vogelstein B (1993): Waf1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
17. El-Deiry W, Harper J, O'Connor P, Velculescu V, Canman C, Jackman J, Pietenpol J, Burrell M, Hill D, Wang Y, Wiman K, Mercer W, Kastan M, Kohn K, Elledge S, Kinzler K, Vogelstein B (1994): WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174.
18. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M (1989): Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86: 8763-8767.
19. Esteve A, Lehman T, Jiang W, Weinstein I, Harris C, Ruol A, Peracchia A, Montesano R, Hollstein M (1993): Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. Mol Carcinogen 8:306-311.
20. Fakharzadeh S, Trusko S, George D (1991): Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10:1565-1569.
21. Finlay C (1993): The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13:301-306.
22. Finlay C, Hinds P, Tan T-H, Oren M, Levine A (1988): Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531-539.
23. Finlay C, Hinds P, Levine A (1989): The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093.
24. Florenes V, Maelandsmo G, Forus A, Andreassen A, Mykleost O, Fodstad O, Flrenes V (1994): MDM2 gene amplification and transcript levels in human sarcomas: Relationship to TP53 gene status. J Natl Cancer Inst 86:1297-1302.
25. Foulkes W, Stamp G, Afzal S, Lalani N, McFarlane C, Trowsdale J, Campbell I (1995): MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer 72:883-888.
26. Graeber T, Osmanian C, Jacks T, Housman D, Koch C, Lowe S, Giaccia A (1995): Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88-91.
27. Greenblatt M, Bennett W, Hollstein M, Harris C (1994): Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
28. Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu W, Takahashi R, Sugiyama T, Yoshida O (1994): Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 86:1331-1335.
29. Haines D, Landers J, Engle L, George D (1994): Physical and functional interactions between wild-type p53 and mdm2 proteins. Mol Cell Biol 14:1171-1178.
30. Harper J, Adami G, Wei N, Keyomarsi K, Elledge S (1993): The p21 Cdk-interacting protein CIP1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
31. Harvey D, Levine A (1991): p53 alteration is a common event in the spontaneous immortalization of primary Balb/c murine embryo fibroblasts. Genes Dev 5:2375-2385.
32. Haupt Y, Barak Y, Oren M (1996): Cell type-specific inhibition of p53 mediated apoptosis by mdm2. EMBO J 15: 1596-1606.
33. He J, Reifenberger G, Liu L, Collins V, James C (1994): Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chromosomes Cancer 11: 91-96.
34. Hinds P, Finlay C, Quartin R, Baker S, Fearon E, Vogelstein B, Levine A (1990): Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: A comparison of the "hot spot" mutant phenotypes. Cell Growth Differ 1:571-580.
35. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris C (1996): Somatic point mutations in the p53 gene of human tumors and cell lines: Updated compilation. Nucleic Acids Res 24:141-146.
36. Horikoshi N, Usheva A, Chen J, Levine A, Weinmann R, Shenk T (1995): Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol Cell Biol 15:227-234.
37. Huibregtse J, Scheffner M, Howley P (1991): A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 13:4129-4135.
38. Jacks T, Remington L, Williams B, Schmitt E, Halachmi S, Bronson R, Weinberg R (1994): Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1-7.
39. Jones S, Roe A, Donehower L, Bradley A (1995): Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-208.
40. Kastan M, Onyinye O, Sidransky D, Vogelstein B, Craig R (1991): Participation of p53 in the cellular response to DNA damage. Cancer Res 51:6304-6311.
41. Kastan M, Zhan Q, El-Deiry W, Carrier F, Jacks T, Walsh W, Plunkett B, Vogelstein B, Fornace A (1992): A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597.
42. Kessis T, Slebos R, Han S, Shah K, Bosch X, Munoz N, Hedrick L, Cho K (1993): p53 gene mutations and MDM2 amplifications are uncommon in primary carcinomas of the uterine cervix. Am J Pathol 143:1398-1405.
43. Khatib Z, Matsushime H, Valentine M, Shapiro D, Sherr C, Look A (1993): Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 53:5535-5541.
44. Kondo S, Barnett G, Hara H, Morimura T, Takeuchi J (1995): MDM2 protein confers the resistance of a human glioblastoma cell line to cis-platin-induced apoptosis. Oncogene 10:2001-2006.
45. Ladanyi M, Cha C, Lewis R, Jhanwar S, Huvos A, Healey J (1993): MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53:16-18.
46. Ladanyi M, Lewis R, Jhanwar S, Gerald W, Huvos A, Healey J (1995): MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol 175:211-217.
47. Landers J, Haines D, Strauss III J, George D (1994): Enhanced translation: A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9:2745-2750.
48. Leng P, Brown D, Shivakumar C, Deb S, Deb SP (1995): N terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene 10:1275-1282.
49. Levine A (1990): The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology 177:419-426.
50. Lianes P, Orlow I, Zhang Z, Oliva M, Sarkis A, Reuter V, Cordon-Cardo C (1994): Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 86:1325-1330.
51. Lin J, Chen J, Elenbaas B, Levine A (1994): Several hydrophobic amino acids in the p53 N-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55 kd protein. Genes Dev 8:1235-1246.
52. Liu X, Miller C, Koeffler P, Berk A (1993): The p53 activation domain binds the TATA box-binding polypeptide in holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol Cell Biol 13:3291-3300.
53. Lowe S, Ruley E, Jacks T, Housman D (1993): p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967.
54. Lu H, Levine A (1995): TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci USA 92:5154-5158.
55. Maestro R, Gloghini A, Doglioni C, Gasparotto D, Vukosavljevic T, De Re V, Laurino L, Carbone A, Boiocchi M (1995): MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. Blood 85:3239-3246.
56. Maltzman W, Czyzyk L (1984): Irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689-1694.
57. Marchetti A, Buttitta F, Girlando S, Dall Palma P, Pellegrini S, Fina P, Doglioni C, Bevilacqua G, Barbareschi M (1995): mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 175:31-38.
58. Marchetti A, Buttitta F, Pellegrini S, Merlo G, Chella A, Angeletti CA, Bevilacqua G (1995b): mdm2 gene amplification and overexpression in non-small cell lung carcinoma with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 4:93.
59. Martin K, Trouche D, Hagemeier C, Sorensen T, La Thangue N, Kouzarides T (1995): Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694.
60. Martinez J, Georgoff I, Martinez J, Levine A (1991): Cellular localization and cell cycle regulation by a temperature sensitive p53 protein. Genes Dev 5:151-159.
61. McCann A, Kirley A, Carney D, Corbally N, Magee H, Keating G, Dervan P (1995): Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 71:981-985.
62. Mercer W, Shields M, Amin M, Suave G, Appella E, Romano J, Ullrich S (1990): Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87:6166-6170.
63. Michalovitz D, Halevy O, Oren M (1990): Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant p53. Cell 62:671-680.
64. Moll U, Riou G, Levine A (1992): Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc Natl Acad Sci USA 89:7262-7266.
65. Moll U, LaQuaglia M, Benard J, Riou G (1995): Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92:4407-4411.
66. Moll U, Ostermeyer A, Haladay R, Winkfield B, Frazier M, Zambetti G (1996): Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol 16:1126-1137.
67. Momand J, Zambetti G (1996): Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene 12:2279-2289.
68. Momand J, Zambetti G, Olson D, George D, Levine A s (1992): The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69:1237-1245.
69. Montes de Oca Luna R, Wagner D, Lozano G (1995): Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206.
70. Nakayama T, Toguchida J, Wadayama B, Kanoe H, Kotoura Y, Sasaki M (1995): MDM2 gene amplification in bone and soft-tissue tumors: Association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer 64:342-346.
71. Nilbert M, Rydholm A, Willen H, Mitelman F, Mandahl N (1994): MDM2 gene amplification correlates with ring chromosomes in soft tissue tumors. Genes Chromosomes Cancer 9:261-265.
72. Oliner J, Kinzler K, Meltzer P, George D, Vogelstein B (1992): Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83.
73. Oliner J, Pietenpol J, Thiagalingam S, Gvuris J, Vogelstein B (1993): Oncoprotein MDM2 conceals the activation domain of tumor suppressor-p53. Nature 362:857-860.
74. Olson D, Marechal V, Momand J, Chen J, Romocki C, Levine A (1993): Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 8:2353-2360.
75. Otto A, Deppert W (1993): Upregulation of mdm-2 expression in METH A tumor cells tolerating wild-type p53. Oncogene 8:2591-2603.
76. Pedeutour F, Suijkerbuijk R, Forus A, Van Gaal J, Van de Klundert W, Coindre J, Nicolo G, Collin F, Van Haelst U, Huffermann K (1994): Complex composition and co-amplification of SAS and MDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcoma. Genes Chromosomes Cancer 10:85-94.
77. Perry ME, Piette J, Zawadzki J, Harvey D, Levine AJ (1993): The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 90:11623-11627.
78. Picksley SM, Vojtesek B, Sparks A, Lane D (1994): Immunochemical analysis of the interaction of p53 with MDM2-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9:2523-2529.
79. Price B, Park S (1994): DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells. Cancer Res 54:896-899.
80. Quesnel B, Preudhomme C, Fournier J, Fenaux P, Peyrat J (1994a): MDM2 gene amplification in human breast cancer. Eur J Cancer 30A:982-984.
81. Quesnel B, Preudhomme C, Oscier D, Lepelley P, Collynd'Hooghe M, Facon T, Zandecki M, Fenaux P (1994b): Over-expression of the MDM2 gene is found in some cases of haematological malignancies. Br J Haematol 88:415-418.
82. Reifenberger G, Liu L, Ichimura K, Schmidt E, Collins V (1993): Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53:2736-2739.
83. Ridge S, Dyer M, Greaves M, Wiedemann L (1994): Lack of MDM2 amplification in human leukemia. Br J Haematol 86:407-409.
84. Riou G, Barrois M, Prost S, Terrier M, Theodore C, Levine A (1995): The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol Carcinogen 12:124-131.
85. Scheffner MB, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990): The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
86. Seto E, Usheva A, Zambetti G, Momand J, Horikoshi N, Weinmann R, Levine A, Shenk T (1992): Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci USA 89:12028-12032.
87. Shibagaki I, Tanaka H, Shimada Y, Wagata T, Ikenaga M, Imamura M, Ishizaki K (1995): p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Clin Cancer Res 1:769-773.
88. Smith M, Chen I, Zhan Q, Bae I, Chen C, Gilmer T, Kastan M, O'Connor P, Fornace A (1994): Interaction of the 3-regulated protein GADD45 with proliferating cell nuclear antigen. Science 266:1376-1380.
89. II60. Science 267:100-103.
90. Truant R, Xiao H, Ingles J, Greenblatt J (1993): Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. J Biol Chem 268:2284-2287.
91. Waber P, Chen J, Nisen P (1993): Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res 53:6028-6030.
92. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T, Saito H (1994): The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84:3158-3165.
93. Wu X, Bayle JH, Olson D, Levine AJ (1993): The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7:1126-1132.
94. Xiao Z-X, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM (1995): Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694-698.
95. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991): Wild-type p53 induces apoptosis of my eloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347.
96. Zambetti GP, Levine AJ (1993): A comparison of the biological activities of wild-type and mutant p53. FASEB J 8:855-865.
97. Zauberman A, Barak Y, Ragimov N, Levy N, Oren M (1993): Sequence-specific DNA binding by p53: Identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J 12:2799-2808.
98. Zhan Q, Lord KA, Alamo Jr I, Hollander MC, Carrier F, Ron D, Kohn KW, Hoffman B, Lieberman D, Fornace Jr AJ (1994): The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Mol Cell Biol 14:2361-2371.